Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALOPRIM vs DUZALLO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Allopurinol inhibits xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine and xanthine to uric acid, thereby reducing serum and urinary uric acid concentrations.
DUZALLO (allopurinol) is a xanthine oxidase inhibitor that reduces uric acid production by inhibiting the conversion of hypoxanthine to xanthine and xanthine to uric acid.
FDA-approved: Management of hyperuricemia in gout, management of hyperuricemia in patients with recurrent uric acid stones, and prevention of tumor lysis syndrome in patients receiving chemotherapy.,Off-label: Prevention of calcium oxalate calculi, management of hyperuricemia in patients with renal impairment, and treatment of Lesch-Nyhan syndrome.
Management of signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy),Prevention of tumor lysis syndrome in patients receiving chemotherapy for leukemia, lymphoma, or solid tumor malignancies
300 mg orally once daily; may be increased to 600-800 mg/day in divided doses for severe gout.
Adults: 200 mg orally twice daily.
Allopurinol: 1-2 h; Oxypurinol: 18-30 h (prolonged in renal impairment, up to 7 days in severe CKD)
Terminal elimination half-life is approximately 12 hours (range 10–14 hours), allowing twice-daily dosing for steady-state achievement within 2–3 days.
Allopurinol is metabolized primarily by xanthine oxidase to its active metabolite, oxypurinol. Both allopurinol and oxypurinol are further metabolized to a lesser extent by aldehyde oxidase.
Primarily metabolized by aldehyde oxidase to oxipurinol, the active metabolite. Also metabolized via xanthine oxidase. Bioactivation requires hepatic metabolism.
Renal: ~70% (30% as allopurinol, 40% as oxypurinol); fecal: ~20%; biliary: minor (<5%)
Primarily renal excretion (approximately 70% as unchanged drug); biliary/fecal excretion accounts for about 20%; the remainder undergoes hepatic metabolism.
Allopurinol: <1%; Oxypurinol: ~20% (primarily to albumin)
Approximately 95% bound primarily to albumin and alpha-1-acid glycoprotein.
Allopurinol: 0.6-1.6 L/kg (suggests distribution in total body water); Oxypurinol: 0.6-1.0 L/kg
Volume of distribution is 0.3–0.5 L/kg, indicating distribution primarily into extracellular fluid and well-perfused tissues.
Oral: 67-90% (allopurinol); rapidly converted to oxypurinol
Oral bioavailability is 60%–70% (first-pass metabolism); intravenous bioavailability is 100%.
GFR 30-60 m L/min: start at 200 mg/day; GFR 10-29 m L/min: 100 mg/day; GFR <10 m L/min: 100 mg every other day or 50 mg/day.
Not recommended in patients with severe renal impairment (e GFR < 30 m L/min/1.73 m²). No dose adjustment required for mild to moderate impairment (e GFR ≥ 30 m L/min/1.73 m²).
No specific adjustment recommended; use with caution in severe hepatic impairment.
No dose adjustment recommended for mild hepatic impairment (Child-Pugh A). Not recommended in moderate or severe hepatic impairment (Child-Pugh B or C).
Children 10-20 mg/kg/day in 2-3 divided doses, maximum 400 mg/day.
Safety and efficacy not established in pediatric patients (< 18 years).
Initiate at lower doses (e.g., 100 mg/day) due to age-related renal decline; monitor for adverse effects.
No specific dose adjustment required; monitor renal function due to age-related decline.
Allopurinol has been associated with hypersensitivity reactions including severe skin reactions such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), which can be life-threatening. The risk is higher in patients with renal impairment and those receiving thiazide diuretics. Discontinue at first sign of rash or other signs of hypersensitivity.
There is no FDA black box warning for DUZALLO.
Risk of severe hypersensitivity reactions including SJS/TEN; increased risk in patients with renal impairment or concomitant thiazide use. Monitor for rash. Acute gout attacks may increase during early therapy; prophylaxis with colchicine or NSAIDs is recommended. Hepatic and renal function should be monitored. May cause drowsiness or dizziness.
Hypersensitivity reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis,Acute gout flare upon initiation; may require prophylactic anti-inflammatory therapy,Renal impairment: dose adjustment required,Hepatic toxicity may occur,Elevated risk of skin rash with concurrent amoxicillin or ampicillin use
Absolute: Patients with a history of a severe hypersensitivity reaction to allopurinol. Relative: Renal impairment (dose adjustment needed), pregnancy (only if benefit outweighs risk), and lactation (use caution).
Hypersensitivity to allopurinol or any component of the formulation,Concomitant use with didanosine
Avoid high-purine foods (e.g., organ meats, anchovies, sardines, mussels, scallops, red meat, beer) as they may increase serum uric acid levels and reduce drug efficacy. Maintain adequate hydration to prevent urate nephropathy. Grapefruit juice has no known interaction. No significant interaction with caffeine.
Avoid grapefruit and grapefruit juice due to potential CYP3A4 inhibition increasing elagolix levels. High-fat meals may slightly increase elagolix absorption but no dose adjustment needed. No other significant food interactions reported.
First trimester: No evidence of teratogenicity in humans; animal studies show no fetal harm. Second/third trimester: No known risks; allopurinol crosses placenta but no congenital anomalies reported. Postnatal: No adverse effects reported.
DUZALLO (allopurinol) is generally considered low risk. First trimester: limited data, no increased malformations. Second/third trimester: no known fetal harm. However, use only if clearly needed.
Allopurinol and its metabolite oxypurinol are excreted in breast milk; M/P ratio not established. No adverse effects reported in nursing infants. Use with caution, especially in infants with G6PD deficiency.
Allopurinol and its metabolite oxypurinol are excreted into breast milk. M/P ratio: 1.4 for allopurinol, 2.5 for oxypurinol. No adverse effects reported in infants; compatible with breastfeeding, but monitor infant for rash.
No dose adjustment required based on pregnancy alone. However, dose may need adjustment if renal function declines. Allopurinol pharmacokinetics not significantly altered in pregnancy; maintain dose based on renal function and uric acid levels.
No specific dose adjustments recommended for pregnancy. Monitor renal function; reduce dose if creatinine clearance decreases. Standard adult dosing: 100-300 mg/day, may be increased up to 800 mg/day under guidance.
Initiate therapy after acute gout flare has subsided; consider gradual dose titration to reduce flare risk; monitor for hypersensitivity reactions, especially in patients with renal impairment; use with caution in patients on thiazide diuretics or ACE inhibitors due to increased risk of hypersensitivity; assess renal function before starting and during therapy; adjust dose in renal impairment (Cr Cl <60 m L/min); avoid use with azathioprine or mercaptopurine unless dose reduction of these agents is implemented; educate patient to report rash, fever, or lymphadenopathy immediately.
DUZALLO (elagolix/estradiol/norethindrone acetate) is a Gn RH antagonist combination product for management of heavy menstrual bleeding in premenopausal women with uterine leiomyomas. Monitor bone mineral density with prolonged use beyond 6 months; avoid in patients with osteoporosis risk factors. Contraindicated with strong CYP3A4 inhibitors and in pregnancy. Assess for mood changes and depression. Use effective non-hormonal contraception during treatment.
Take this medication exactly as prescribed, usually once daily.,Do not start or stop taking this medication during an acute gout attack; wait until the flare has resolved.,Drink plenty of fluids (at least 2 liters of water per day) unless otherwise directed by your doctor.,Avoid alcohol and foods high in purines (e.g., red meat, organ meats, shellfish) as they may increase uric acid levels.,Report any skin rash, itching, swelling, or difficulty breathing to your doctor immediately.,Inform your doctor of all medications you are taking, including over-the-counter drugs and supplements.,Do not take this medication with azathioprine, mercaptopurine, or theophylline unless specifically instructed by your doctor.,Store at room temperature away from moisture and heat.
Take one tablet daily at approximately the same time with or without food.,Missing doses increases risk of pregnancy and reduces effectiveness for bleeding control.,Use effective non-hormonal contraception (e.g., condoms, copper IUD) during treatment and for 2 weeks after discontinuation.,Report severe headache, chest pain, or vision changes immediately (risk of thromboembolic events).,Notify your doctor if you suspect pregnancy or develop heavy bleeding, worsening depression, or jaundice.,Bone density may decrease; calcium and vitamin D supplementation is recommended.,Avoid grapefruit or grapefruit juice during treatment.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALOPRIM vs DUZALLO, answered by our medical review team.
ALOPRIM is a Xanthine Oxidase Inhibitor that works by Allopurinol inhibits xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine and xanthine to uric acid, thereby reducing serum and urinary uric acid concentrations.. DUZALLO is a Xanthine Oxidase Inhibitor that works by DUZALLO (allopurinol) is a xanthine oxidase inhibitor that reduces uric acid production by inhibiting the conversion of hypoxanthine to xanthine and xanthine to uric acid.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALOPRIM and DUZALLO depend on the specific clinical indication. These are both Xanthine Oxidase Inhibitor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALOPRIM is: 300 mg orally once daily; may be increased to 600-800 mg/day in divided doses for severe gout.. The standard adult dose of DUZALLO is: Adults: 200 mg orally twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALOPRIM and DUZALLO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALOPRIM is classified as Category C. First trimester: No evidence of teratogenicity in humans; animal studies show no fetal harm. Second/third trimester: No known risks; allopurinol crosses placenta but no congenital . DUZALLO is classified as Category C. DUZALLO (allopurinol) is generally considered low risk. First trimester: limited data, no increased malformations. Second/third trimester: no known fetal harm. However, use only if. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.